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Background: Current treatments for Myelofibrosis (MF) are largely palliative, with ruxolitinib being 
the breakthrough treatment approved for higher-risk patients by the Food and Drug Administration in 
November of 2011. Little is known about the “real-world” patterns of care and outcomes of MF patients 
since the introduction of ruxolitinib. Patients and Methods: The SEER-Medicare database was used to 
identify older patients diagnosed with MF from 2007 through 2015. Treatment patterns were assessed 
using Medicare part B and D claims, and multivariate cox proportional hazards regression models were 
used to assess the effect of ruxolitinib use on survival in MF patients. Results: A total of 773 patients 
were identified. The median age of our study population (N=773) was 76 years (IQR, 70, 80), and 
88.9% of the population was non-Hispanic white. Of 342 patients who were diagnosed during 2012-
2015 (i.e., the ruxolitinib era), 127 (37.1%) were ruxolitinib users. The median duration of ruxolitinib 
use was 16.21 months. Most ruxolitinib users started with doses of 5 (23.6%), 10 (27.0%), or 20 (23.6%) 
mg twice a day (BID). Among the patients who started treatment at 5 mg BID, 56.6% were never able to 
increase the dose above 5 BID. Only 3.1% were able to use the maximum dose of 25 mg BID. 54.3% of 
patients were taking hydroxyurea or prednisone during the same time period that they took ruxolitinib. 
Medications to manage anemia were used more commonly by MF patients diagnosed before 2012. 
Among patients diagnosed in 2012-2015, there was no difference in survival between ruxolitinib users 
and non-users. Conclusion: Older MF patients treated with ruxolitinib had similar survival when 
compared to patients who did not receive this medication but possibly belonged to the lower disease risk 
group. For many ruxolitinib users, the dose of ruxolitinib could not be escalated, additional medications 
were used concurrently, and the drug was discontinued quickly after initiation. Optimization of 
ruxolitinib use may be necessary to accomplish better outcomes. Furthermore, development of new 
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Myelofibrosis (MF) is a type of Philadelphia chromosome negative myeloproliferative neoplasm 
(MPN), characterized by bone marrow fibrosis, systemic and splenomegaly-related symptoms, 
cytopenias and abnormal extramedullary hematopoiesis (Barosi 1999, Cervantes et al. 2009). MF can be 
primary or secondary when it develops after Polycythemia Vera (PV) or Essential Thrombocythemia 
(ET). It is a rare disease with incidence of approximately 0.1 to 1 per 100,000 people per year (Moulard 
et al. 2014). The median age of diagnosis is approximately 67 years, and the median survival is 3 to 7 
years (Mesa et al. 1999, Kvasnicka et al. 2000). Arterial and venous thrombosis, the common feature in 
MPNs, may occur among patients with MF with the rate of 0.95% to 1% patients per year (Guglielmelli 
et al 2020). 
There are a variety of treatments used to manage MF, however, most of them fall into the category of 
supportive care. The only known disease-modifying treatment capable of curing MF is allogeneic 
hematopoietic stem cell transplantation (allo HSCT) which, due to its high morbidity and mortality, is 
reserved for younger patients who have higher-risk disease based on clinical and laboratory parameters 
including cytogenetic and molecular data (Tefferi 2016). Other treatments are used to control disease-
related symptoms including hydroxyurea, prednisone and spleen-directed therapies such as splenectomy 
and splenic irradiation. Also, erythropoiesis-stimulating agents, androgens (e.g. danazol), and 
immunomodulatory IMID drugs (IMIDs, with or without steroids) are used to improve anemia (Tefferi 
2016). 
Since the early 2000s, discovery of driver mutations and an improved understanding of the molecular 
pathophysiology of MF have led to the development of new therapeutic approaches to this disease 
(Wadleigh and Tefferi 2010).  In November 2011, the United States Food and Drug Administration 
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(FDA) approved an oral JAK-inhibitor, ruxolitinib, for treatment of MF patients who are considered 
intermediate- or high- risk based on the International Prognostic Scoring System (IPSS). This was based 
on the results of two phase 3 randomized studies which showed significant reduction of spleen size and 
improvement of symptoms among IPSS intermediate-2 and high-risk patients with MF when compared 
to placebo (Verstovsek et al. 2012) and to best available therapy (Harrison et al. 2012). Ruxolitinib was 
also shown in post-hoc analyses to improve overall survival (Mesa et al. 2014, Verstovsek 2012 and 
Verstovsek 2015).  
One of the common toxicities of ruxolitinib is worsening of anemia, and management is not well defined 
in this setting. Some patients require short or long-term red blood cell transfusions and others utilize 
anemia-directed therapies similar to non-ruxolitinib treated patients without good evidence to support 
this approach (Barbui et al. 2018). 
There are very limited data on the “real-world” clinical experiences and outcomes of patients with MF 
who are treated in the JAK inhibitor era (Mascarenhas et al. 2020). MF became reportable to population-
based cancer registries such as the Surveillance, Epidemiology and End Results (SEER) program in 
2001, making it possible to assess the incidence and survival of MF at the population level. Therefore, 
the objective of this study is to understand the “real-world” patterns of care and outcomes of older adults 
with MF since ruxolitinib became available for their management. 
Methods 
Data Source 
The SEER-Medicare linked database, developed by the National Cancer Institute (NCI) and the Centers 
for Medicare and Medicaid Services, links patient-level information from the SEER records with 
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Medicare enrollment and claims data. The SEER database contains 17 SEER regions, collects data on 
survival and demographic information and covers approximately 34% of the United States population 
(NCI 2019). The Medicare database includes data for inpatient, outpatient, physician services and 
prescription drugs (Warren et al. 2002). Since the median age of MF diagnosis is 67 years old, the 
SEER-Medicare database is a good data source to analyze the outcomes and treatment patterns of older 
MF patients (Mesa et al. 1999).  The most recent SEER-Medicare database includes MF patients 
diagnosed between 2001 and 2015, with Medicare claims through the end of 2016. The Yale Human 
Investigation Committee determined that this study did not directly involve human subjects. 
Study Population  
Since we needed to access Medicare Part D claims for the use of oral prescription drugs and Part D was 
not available until 2006, we assembled a retrospective cohort of patients diagnosed with incident MF 
(International Classification of Diseases for Oncology, Third Edition codes: 9961) between 2007 and 
2015. All patients fulfilled the following eligibility criteria: 1) aged 66-99 years at diagnosis; 2) had 
known month of diagnosis; 3) were not identified from death certificate or autopsy only; 4) had 
continuous enrollment in Medicare Part D from diagnosis 5) had continuous enrollment in Medicare 
Parts A, B and no enrollment in health maintenance organizations from 1 year before diagnosis until the 
end of follow-up (death or 12/31/2016, whichever came first); and 6) bone marrow biopsy claim from 1 
year before diagnosis to end of follow up.  
Treatment Assessment  
Prescription drug use was identified from the Medicare Part B and D claims using clinical modification 
procedure codes (ICD-9 and ICD-10), the Healthcare Common Procedure Coding System (HCPCS) 
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codes, and brand or generic name for oral drugs from Medicare claims. Prescription drug users were 
defined as any patient that used the drug between the date of diagnosis and end of follow up. Allo 
HSCT, splenectomy and splenic irradiation were assessed using ICD-9, ICD-10 and HCPCS codes. 
Anemia drugs included: Darbepoeitin, Epogen, androgens [testosterone and danazol] and IMIDs 
[lenalidomide and thalidomide].   
The daily dose of ruxolitinib at initiation was assessed by using the patient’s first ruxolitinib prescription 
via the formula [daily dose = (dose strength (mg)*quantity dispensed)/ number of days supplied]. We 
calculated the end date of last dispense as dispense date plus number of days supplied, if the end date 
exceeded the end of follow-up, we censored at the date of end of follow-up. Duration of ruxolitinib was 
calculated as the difference between the first prescription date and end date of last dispense. We 
restricted calculation of duration among patients with more than one ruxolitinib prescription. To 
understand the use of concurrent drugs with ruxolitinib, we also assessed patients’ prescriptions on 
prednisone and hydroxyurea within 1 month after ruxolitinib initiation and 1 month before 
discontinuation of ruxolitinib, which was designated as the patient’s last prescription. 
Outcome and Variable Assessment  
Our primary outcome of interest was overall survival (OS). Patients were followed from the date of their 
diagnosis until death or the end of the study period (December 31st, 2016), whichever came first.  
We obtained information on the following patient characteristics: age at diagnosis, sex, race/ethnicity, 
marital status, comorbidities, SEER region (West, South, Midwest, or Northeast) and census tract 
median household income. To assess comorbidities, we used ICD-9 and ICD-10 diagnosis codes within 
1 year prior to MF diagnosis in inpatient claims or at least 2 outpatient claims, 30 days apart. A modified 
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Elixhauser score was developed previously by our research group by removing prior thrombosis from 
the original Elixhauser score (Wang et al. 2017).  
Statistical Analysis 
Categorical variables were presented using frequencies and percentages. Continuous variables were 
summarized by median and interquartile range (IQR). F-test for continuous variables and χ2 test for 
categorical variables was used to compare treatment groups. Consistent with the SEER-Medicare 
requirement to preserve confidentiality, all categories with ≤ 10 patients were reported as <11. Kaplan-
Meier curves and log-rank tests were used to compare the incidence of death between treatment groups. 
Multivariable Cox proportional hazards regression models with time dependent variables were used to 
identify potential predictors of survival. A ruxolitinib user would only be considered as a user after the 
initiation. Aside from treatments, we considered the possible influence of several patient characteristics 
on OS, including age of diagnosis, sex, race/ethnicity, marital status, and comorbidities. All analyses 
were conducted using SAS 9.4 (SAS Institute Inc., Cary, North Carolina) with two-sided tests and a type 
I error of 0.05 as the threshold for statistical significance. 
Results 
Study Population and Baseline Characteristics  
We identified a total of 773 patients who fulfilled the eligibility criteria. The median age at diagnosis 
was 75 years (IQR, 70-80 years), 88.9% were non-Hispanic white, 55.1% were male, and 55.8% (N= 
431) were diagnosed before 2012.  
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Since ruxolitinib was approved to treat MF in November 2011, we further categorized our study 
population into two groups: early era (diagnosed during 2007- 2011) and late era (diagnosed during 
2012-2015). Patients diagnosed in the two eras were similar with respect to all characteristics except for 
death at the end of the study period (p<0.001), comorbidities (p<0.001), SEER region (p=0.03) and 
median household income (p<0.001) (Table 1).  
The 342 patients who were diagnosed in the later era were further categorized into two groups based on 
ruxolitinib use. A total of 127 (37.1%) patients ever used ruxolitinib after diagnosis. As shown in Table 
2, there was no difference among any evaluated characteristics.  
Treatment Patterns and Outcomes 
To compare the pattern of treatment between the two eras, we censored the patients diagnosed in the 
early era at the end of 2011. More patients diagnosed in the later era used hydroxyurea (39.2%) than 
those diagnosed earlier (26.7%). However, more patients diagnosed in the early era used anemia-
directed therapies (34.3% vs. 19.9%) and prednisone (36.2% vs. 30.1%) compared to those diagnosed 
later (Figure 1). 
Only a limited number (<11) of ruxolitinib users and non-users received splenic irradiation. There were 
27 patients (7.9%) in the ruxolitinib era group who were 70 or younger at the time of MF diagnosis, and 
out of these 27, less than 11 patients received allo HSCT.  
The median time to initiation of ruxolitinib after MF diagnosis was 107 days (IQR, 47, 341.7 days, 
N=127), and the majority of patients started at daily doses of 10, 20 or 40 milligrams (mg), which is 5, 
10 and 20 mg per time twice a day (BID) (Figure 2). Of the 30 patients who started at 5 mg BID, 17 
(56.7%) never had their dose of ruxolitinib escalated above 5 mg BID. Also, less than 11 patients were 
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able to go up to the highest dose of 25 mg BID. The median amount of time patients stayed on 
ruxolitinib was 16.21 months (Figure 3). While on ruxolitinib treatment, 28 (22%) and 17 (13%) also 
took hydroxyurea and prednisone, respectively. In addition, 12 (10%) ruxolitinib treated patients took 
both hydroxyurea and prednisone during the same time period (Figure 4).  
Ruxolitinib users had similar survival to non-user survival, with a median survival of 2.93 years in the 
ruxolitinib treatment group and a median survival of 2.59 years in the non-ruxolitinib treatment group 
(Figure 5). The percent of patients that died in each group was also similar: 48.84% died in the non-
ruxolitinib treatment group and 52% died in the ruxolitinib treatment group. In the multivariable 
analysis, the risk of death among ruxolitinib users compared to non-users was not statistically significant 
(p=0.33, Figure 5). 
Discussion 
In this retrospective population-based study that reflects real-world clinical practice, we assessed the 
management of older patients diagnosed with MF in the real-world setting with a focus on the impact of 
ruxolitinib, which was approved by the FDA in November 2011. Among patients diagnosed in 2012-15, 
127 (37.1%) patients received ruxolitinib, with a median of 107 days to treatment initiation, and a 
median duration of use of 16.21 months. About half of ruxolitinib users initiated treatment at low doses 
(up to 10 mg BID). Although we did not observe any difference in survival between ruxolitinib users 
and non-users, taking into consideration that ruxolitinib has been approved for higher risk MF patients, 




We found that lower initiation doses were common among older MF patients. Over half of ruxolitinib 
users started at 5 or 10 mg BID, and only about 23% started at 20 mg BID, which is a maximal initiating 
dose based on FDA approved drug prescription information (FDA 2019). The recommended dose at the 
time of treatment initiation is based on patient’s platelet count: 20 mg, 15 mg and 5 mg BID for those 
with platelets >200,000/mm3, 100,000 to 200,000/mm3, and 50,000 to <100,000/mm3, respectively 
(FDA 2019). A dose of 5 mg BID is less effective than higher doses to accomplish symptom control and 
decrease spleen size (Talpaz et al. 2013). However, 13.4% of ruxolitinib users in our study were never 
prescribed a dose above 5 mg BID. This could be related to low platelet counts or concerns about side 
effects, including anemia. Less than 11 (3.1%) patients were able to escalate their dosing to the highest 
recommended dose of 25 mg BID, which should be considered if treatment results with lower doses are 
unsatisfactory and if the patient is expected to tolerate dose escalation.  
Many patients received both ruxolitinib and other symptom-directed therapies (including hydroxyurea 
and/or steroids) at the same time, pointing to less than acceptable symptom control by ruxolitinib alone. 
This could be related to lower doses of ruxolitinib being used by our patients. It is interesting that more 
patients diagnosed after 2011 used hydroxyurea more than patients managed in the pre ruxolitinib era. A 
more focused approach by providers to symptom control in ruxolitinib era can explain the wider use of 
symptom-directed therapies. Even though ruxolitinib was added to management and hydroxyurea use 
increased, anemia-directed drug therapies, expected to have higher demand in the setting of these 
cytoreductive treatments, were used less frequently after 2011. This may be related to lack of evidence 
behind concurrent use of these drugs with ruxolitinib, which is antagonistic to erythropoietin analogues 
based on its mechanism of action. 
As expected, very few patients in our cohort (N<11, 1.5%) received spleen-directed therapies before and 
after introduction of ruxolitnib. Splenectomy is associated with high morbidity, including liver 
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enlargement and failure, thrombocytosis, thrombosis, intrabdominal infection and increased rate of blast 
transformation as well as 30% perioperative morbidity and 10% mortality. Splenic irradiation is 
associated with long-lasting cytopenias and transfusion dependence (Tefferi et al. 2000). The number of 
cases receiving spleen-directed therapies is expected to decrease in the era of ruxolitinib due to its 
successful ability to decrease spleen size, but we could not perform this analysis due to low frequency of 
the above described procedures.  
Even though allo HSCT is the only disease modifying treatment for MF, very few patients received 
transplant in our study. Only 27 among 342 patients (7.9%) were transplanted. The average age of our 
patient population was 76 years, which may explain infrequent allo HSCT use, as it is usually reserved 
for younger (<70 years old) patients due to high procedure-related morbidity and mortality which 
increases with age. Allo HSCT was not reimbursed by Medicare for MF patients until 2016, which may 
be another reason for low prevalence of this treatment in our patient population.  
Our study has several strengths.  Its population-based design allowed us to evaluate real-world treatment 
of older patients with MF and helped to assemble a large cohort of patients with this rare disease. 
Limitations include short observation period as follow up duration could not exceed 5 years due to 
ruxolitinib only being approved for MF patients since 2011. We also used Medicare claims to identify 
treatments and procedures received by our patients. Therefore, any drugs or procedures not covered by 
Medicare could not be factored into our analyses. As clinical and laboratory variables necessary to 
estimate patients’ risk based on prognostic models utilized in clinical practice (IPSS) were not available, 
we could not factor these risks into multivariable survival analysis. Also, the age of our population is 
about 10 years older than the average age of MF patients at diagnosis which may lead to different 
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outcomes among our patients when compared to the general population with this disease. Finally, 
patterns of care might have been affected by a variety of unknown confounders. 
Conclusion 
This large population-based study of older patients with MF assessed their pattern of care in the 
ruxolitinib era and showed similar survival of ruxolitinib users to non-users who are expected to have 
lower risk disease. Ruxolitinib dose was not escalated above the lowest dose and to the highest 
permitted dose in a large number of patients and treatment was discontinued quickly after initiation.  
Optimization of ruxolitinib use may be necessary to accomplish better outcomes. Furthermore, 
development of new drugs, which may be used with ruxolitinib or after its discontinuation, is needed. 
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Table 1.  Characteristics of 773 older adults with MF, 2007-2015 
 
Characteristic Overall  Year of diagnosis 
   2007-2011 2012-2015 p† 
 N (%)  N (%) N (%)  
Total 773  431 342  
Race/ethnicity     0.20 
     Non-Hispanic 
white 
687(88.9)  383(88.9) 304(88.9)  
     Other 86(11.1)  48(11.1) 38(11.1)  
Age at diagnosis 
(years) 
    0.31 
     Median (IQR) 76(70-80)  76(71-80) 75(70-80)  
Sex     0.46 
     Male 425(55.0)  232(53.8) 193(56.4)  
     Female 348(45.0)  199(46.2) 149(43.6)  
Marital status     0.33 
     Married 417(53.9)  233(54.1) 184(53.8)  
     Unmarried 258(33.4)  154(35.7) 104(30.4)  
     Unknown 98(12.7)  44(10.2) 54(15.8)  
Death at End of 
Study Period 
    <0.001 
     Yes 496(64.2)  330(23.4) 166(48.5)  
     No 277(35.8)  101(76.6) 176(51.5)  
Comorbidities     <0.001 
     0 211(27.3)  118(28.6) 93(27.2)  
     1-2 306(39.6)  175(40.6) 131(38.3)  
     3+ 256(33.1)  138(32.0) 118(34.5)  
SEER Region      0.03 
     West 331(42.8)  181(42.0) 150(43.9)  
     South 149(19.3)  81(18.8) 68(19.9)  
     Midwest 133(17.2)  89(20.7) 44(12.9)  




     
     <33,000 138(17.9)  118(27.4) 20(5.9) <0.001 
     33,000-40,000 56(7.2)  29(6.7) 27(7.9)  
     40,000-50,000 123(15.9)  71(16.5) 52(15.2)  
     >50,000 456(59.0)  213(49.4) 243(71.1)  
* Numbers may not sum to totals due to missing data, and column percentages may not sum to 100% due to rounding. 




Table 2.  Characteristics of 342 older adults with MF by ruxolitinib status, 2012-2015 
 
 Ruxolitinib p† 
 Ever Never  
Characteristic N (%) N (%)  
    
Total 127 215  
Race/ethnicity   0.50 
     Non-Hispanic 
white 
114(89.8) 190(88.4)  
     Other 10(10.2) 25(11.6)  
Age at diagnosis 
(years) 
  0.44 
     Median (IQR) 75(70-80) 75(70-80)  
Sex   0.33 
     Male 76(59.8) 117(54.4)  
     Female 51(40.2) 98(45.6)  
Marital status   0.79 
     Married 69(54.3) 115(53.5)  
     Not married 38(29.9) 66(30.7)  
     Unknown 20(15.7) 34(15.8)  
Death at End of 
Study Period 
  0.89 
     Yes 66(52.0) 105(51.2)  
     No 61(48.0) 110(48.8)  
Comorbidities   0.93 
     0 36(28.3) 57(26.5)  
     1-2 48(37.8) 83(38.6)  
     ≥ 3 43(33.9) 75(34.9)  
SEER Region    0.67 
     West 58(45.7) 92(42.8)  
     South 23(18.1) 45(20.9)  
     Midwest 19(15.0) 25(11.6)  




  0.45 
     <33,000 5(3.94) 15(7.0)  
     33,000-40,000 11(8.66) 16(7.4)  
     40,000-50,000 23(18.1) 29(13.5)  
     >50,000 88(69.3) 155(72.1)  
* Numbers may not sum to totals due to missing data, and column percentages may not sum to 100% due to rounding. 










*Censored patients after 2011 for patients diagnosed before 2012 
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Figure 4. Most commonly used concurrent drugs received by ruxolitinib treated patients (N=127; 
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* Adjusted for age, marital status, gender, comorbidities and race 
 



























Log Rank Test: p= 0.33
 
N at risk at time point 
Time (years) 1 2 3 4 5 
Total 265 147 59 24 0 
Other/None 156 89 37 12 0 
Ruxolitinib 109 58 22 12 0 
Treatment 
Group Total N Died N (%) 
Median 
Survival  Unadjusted HR Adjusted HR 
Other/None 215 105(48.84) 2.59 yrs. 1 1 
Ruxolitinib 127 66(52.00) 2.93 yrs. 0.86(0.62,1.17) 0.86(0.61,1.22) 
 
